Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 15, 2024 09:00 ET | Source: Tevogen Bio Inc

Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares

Tevogen Bio Reports Second Quarter 2024 Financial Results
August 14, 2024 09:00 ET | Source: Tevogen Bio Inc

Tevogen Bio’s Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health

Tevogen Bio congratulates Professor Sten Vermund, MD, PhD on being named as the dean of the USF Health College of Public Health.
August 09, 2024 11:00 ET | Source: Tevogen Bio Inc

Tevogen Bio’s Founding CEO, Ryan Saadi, Expresses Conviction in Company’s Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities

Tevogen Bio reaffirms that the registration statement does not relate to any previously undisclosed new issuances of dilutive securities.
July 11, 2024 12:21 ET | Source: Tevogen Bio Inc

Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback

WARREN, N.J., July 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holding Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing...
July 10, 2024 08:05 ET | Source: Tevogen Bio Inc

Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian

Dr. Flomenberg and Dr. Grosso are leading experts in T cell biology and its clinical applicationsTevogen’s ExacTcell™ platform is designed to address current cost, and patient accessibility...
July 08, 2024 16:07 ET | Source: Tevogen Bio Inc

Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility

WARREN, N.J., July 08, 2024 (GLOBE NEWSWIRE) -- Ryan Saadi, MD, MPH, founding CEO of Tevogen Bio (“Tevogen”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing...
June 26, 2024 12:46 ET | Source: Tevogen Bio Inc

Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities

This new registration statement does not relate to any previously undisclosed new issuances of dilutive securities.
June 25, 2024 08:05 ET | Source: Tevogen Bio Inc

Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances

WARREN, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing...
June 18, 2024 15:17 ET | Source: Tevogen Bio Inc

Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference

Untapped potential and development of a new class of T Cell therapies for large patient populations. Overcoming CAR-T challenges.
June 12, 2024 15:45 ET | Source: Tevogen Bio Inc

Tevogen Bio Set to Join Russell 3000® Index

Tevogen Bio is set to join the Russell 3000® Index effective at the open of US equity markets on Monday, July 1.